Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?
about
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinibThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPEGFR mutations as a prognostic and predictive marker in non-small-cell lung cancerStructures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor SensitivityHER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy.Ovine pulmonary adenocarcinoma: a large animal model for human lung cancerGenome wide SNP comparative analysis between EGFR and KRAS mutated NSCLC and characterization of two models of oncogenic cooperation in non-small cell lung carcinomaCommon Oncogene Mutations and Novel SND1-BRAF Transcript Fusion in Lung Adenocarcinoma from Never SmokersA rapid screening assay to search for phosphorylated proteins in tissue extractsIn-depth analysis shows synergy between erlotinib and miR-34aTAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer CellsPolymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancersClinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancersMolecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC)Pancreatic cancer.Inhibition of EGFR signaling: all mutations are not created equal.High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer.Polymorphisms in the epidermal growth factor receptor gene and the risk of primary lung cancer: a case-control study.High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies.Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.Recurrent genomic gains in preinvasive lesions as a biomarker of risk for lung cancerDeregulated EGFR signaling during lung cancer progression: mutations, amplicons, and autocrine loops.Panel based MALDI-TOF tumour profiling is a sensitive method for detecting mutations in clinical non small cell lung cancer tumour.Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer.Discovering functional modules by identifying recurrent and mutually exclusive mutational patterns in tumors.Allelotypes of lung adenocarcinomas featuring ALK fusion demonstrate fewer onco- and suppressor gene changes.Phase I/II study of gefitinib (Iressa(®)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancerMutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smokingComputational methods and resources for the interpretation of genomic variants in cancerDe novo discovery of mutated driver pathways in cancerNCI's provocative questions on cancer: some answers to ignite discussion.EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib.Chronic Obstructive Pulmonary Disease-Related Non-Small-Cell Lung Cancer Exhibits a Low Prevalence of EGFR and ALK Driver MutationsMutational analysis of the insulin-like growth factor 1 receptor tyrosine kinase domain in non-small cell lung cancer patients.Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas.Epidermal Growth Factor Receptor Mutation Enhances Expression of Cadherin-5 in Lung Cancer CellsCorrelations Between the EGFR Mutation Status and Clinicopathological Features of Clinical Stage I Lung Adenocarcinoma.Statin improves survival in patients with EGFR-TKI lung cancer: A nationwide population-based study.DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer.Cancer genes in lung cancer: racial disparities: are there any?
P2860
Q21563446-C03D4140-238A-4360-8AAC-11E3F02F718EQ24649549-D86CB5CE-8D16-4299-B21D-1AA8BBB8ED00Q26852507-A791652F-11F8-49C1-BD5F-CE424670624EQ27644014-9857B86C-3D55-435F-968C-FF3143DAA989Q27851461-CD338F60-4C15-4D21-8E4F-85DF8B9CDB61Q28088774-B7DCA12A-416F-4F20-93FC-2CFCA9793371Q28385454-C526868A-854B-405F-8DE2-265A2FC8CC65Q28394324-6F54680B-6039-450E-8501-853395E81057Q28485206-273BCBF6-479F-4418-8FDF-8CA6756BDCF4Q28539851-39EE5828-F2EB-443C-9B17-FE41A848844EQ28548485-D36F4488-BE78-4DBC-802C-7016ADBE8923Q28757672-81AEB854-257C-4DE2-B3E0-40732DF4407EQ29615475-E26F25FA-7064-4E71-8890-C6DF0AFC8EB4Q30433431-897CA0EB-AC57-4951-9F6E-D6EB2DE4E6ECQ30490247-DB89469C-1247-425A-8A2D-EF378D31864EQ33227206-6F651BF5-509B-4CF3-9A3D-DBE8DF6B472CQ33267389-EB5C4231-6597-4339-AC96-F24E9D641389Q33303639-7655C034-F1E8-4C00-A83E-2AF28EF993E1Q33336861-E0D82D8B-3855-44E4-8463-FC1B1F7B6805Q33411775-EF32FDA3-0A74-4FA6-9AE0-13FB890BDA97Q33472669-61061382-429B-4F1D-B472-0008B2149D87Q33769820-1799E8E3-3E4B-46AD-A86D-1F434522A352Q33793611-3D8E0AB4-6CE9-43F9-A4FA-33931116C379Q33810641-B0B69976-9B05-4558-B259-33D35BCEF869Q33871743-40247C77-9142-4FC8-AB9D-F67F9846EE51Q34536679-08F35C67-DFDC-4D5D-9B2B-418AFE51F29CQ35123203-E406B9C3-37CD-4055-958F-CEF6F088124FQ35551048-696D28C2-9309-43DA-8857-9B9BA084BC49Q35674603-1D510FD6-EFD9-4877-8512-10FC48497985Q35694415-BD2AAE7D-78BE-4D7B-A141-23F74F58FA92Q35764401-6335E758-FD55-4318-801A-2E340D9B3CC8Q35800614-70338DBC-43FA-4707-878A-9AC628C1F15AQ35837368-8F0F8766-BE94-4848-A0F9-C84254FA75BDQ35948040-3A0FF954-9550-4076-9B48-B0E1012D2C99Q36014004-8CB37956-919C-4C7E-B19B-6CB7C6A09FD5Q36065121-F9E75EA6-ED14-4826-A8E5-9DC35CCECDDAQ36207143-D5ED83C9-6BB4-447F-BAF4-F9468BD3E290Q36269651-68F952E9-E95B-4120-81BF-5BEB829C0B51Q36471888-89FD6668-E64F-4805-9400-CAB353AF3C65Q36481954-D7D7CEBD-5851-4D4A-8A15-6900A3F763CD
P2860
Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?
@ast
Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?
@en
type
label
Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?
@ast
Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?
@en
prefLabel
Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?
@ast
Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?
@en
P2093
P1476
Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?
@en
P2093
Adi F Gazdar
Hisayuki Shigematsu
Joachim Herz
John D Minna
P304
P356
10.1016/J.MOLMED.2004.08.008
P577
2004-10-01T00:00:00Z